प्राथमिक स्रोत रिकॉर्ड
निर्णायकटॉपलाइन परिणाम
JNJ: PROTEUS फेज़ 3 में सर्जरी से पहले/बाद apalutamide + ADT से मेटास्टेसिस/मृत्यु का जोखिम 20% कम
The final analysis of the Phase 3 PROTEUS study met both primary endpoints, demonstrating that apalutamide plus ADT given perioperatively significantly improves pathologic complete response and metastasis-free survival versus ADT alone. These data support a potential new perioperative treatment paradigm for high-risk localized or locally advanced prostate cancer, with regulatory review not yet initiated.
मुख्य तथ्य
- फाइल किया गया
- 31 मई 2026, 12:27 pm
- घटना
- टॉपलाइन परिणाम
- दिशा
- सकारात्मक
- कंपनी
JNJJohnson & Johnson- संपत्ति
- apalutamide
- विश्वसनीयता
- स्रोत सहित
- EFS HR
- 0.71 (29% risk reduction)
- MFS HR
- 0.80 (20% risk reduction)
- 5yr MFS
- 78.2% vs 73.5%
- pCR MRD
- 8.9% vs 1.0% (OR 10.17)
- subsequent therapy
- 74.2 vs 41.5 months
स्रोत का अंश
Johnson & Johnson's Phase 3 prostate cancer study shows ERLEADA® (apalutamide) before and after surgery significantly reduces risk of metastasis or death, breaking a decades-long treatment paradigm Johnson & Johnson's Phase 3 prostate cancer study shows ERLEADA® (apalutamide) before and after surgery significantly reduces risk of metastasis or death, breaking a decades-long treatment paradigm News provided by Johnson & Johnson May 31, 2026, 08:27 ET Share this article Share to X Share this article Share to X Patients were nine times more likely to have little to no cancer remaining in the prostate after surgery, with a 20% reduction in the risk of developing metastasis or death Data selected to open the plenary presentation at ASCO 2026 and published in The New England Journa